Print
Email
Share

NBA great Abdul-Jabbar has rare form of leukemia

Associated Press

Posted on November 10, 2009 at 6:18 PM

NEW YORK (AP) — Basketball great Kareem Abdul-Jabbar is being treated for a rare form of leukemia, and says his prognosis for a full life is encouraging.

The NBA's all-time leading scorer tells The Associated Press that he was diagnosed last December with chronic myeloid leukemia.

The 62-year-old Abdul-Jabbar says doctors told him he has a "very good" chance of a full life without making any drastic changes. He is taking an oral medication for the disease.

Abdul-Jabbar says he went for tests last year after getting hot flashes and sweats on a regular basis. He says he's speaking out to help raise awareness about the blood cancer.

About 5,000 cases of chronic myeloid leukemia are expected to be diagnosed in the United States this year.

Print
Email
Share

Forgot Password?

Don't have an account?

Register Now

Member Benefits

Link your account to your Twitter or Facebook account for easier login!

Link your account to your Facebook profile Link your account to your Twitter profile

Check box to receive Free Special Offers

* - Indicates required field

Check box to receive Free Special Offers

Connecting to

You may need to allow pop up window for this step of registration

Just one more step:

Please take a moment to review the available e-mail newsletters has to offer. Place a checkbox next to the newsletters you wish to subscribe to.

Welcome.

Thank you for becoming a member of WHAS11.com. You now have full access to the best local coverage and late breaking news from WHAS11.com. Soon you will be redirected to the page you were seeking, and a confirmation email will be delivered to you.

You will need to respond to the confirmation e-mail for your account to be activated.

WHAS11.com is dedicated to bringing you exceptional news and outstanding information services, all while personalizing it to your liking. We're sure you'll enjoy being a WHAS11.com member! If you need assistance, please contact us.